glp 1 ag GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential GLP-1 receptor agonists in the

That means treatment is not simply about receiving a prescription

Our 2030 estimates contemplate global penetration into the addressable type 2 diabetes and obesity markets of only 8% and 2%, respectively (from about 3% and 0.2% in 2023). Uptake would likely be greater if these drugs could be consumed in oral form rather than injected, adds the report, An oral weight loss agent would likely be well-received in the primary care setting and could alleviate pressure on supply chains

the hard 90% has to be built

A review by Karagiannis et al

It works in synergy with other anti-oxidants and in particular helps to regenerate the antioxidant capacity of vitamins C and E